Lantern Pharma (LTRN) Competitors $4.00 +0.24 (+6.38%) As of 01:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LTRN vs. GALT, GLSI, RAPT, NMRA, FTLF, ACTU, FATE, CRBU, CRDL, and KRROShould you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Galectin Therapeutics (GALT), Greenwich LifeSciences (GLSI), Rapt Therapeutics (RAPT), Neumora Therapeutics (NMRA), FitLife Brands (FTLF), Actuate Therapeutics (ACTU), Fate Therapeutics (FATE), Caribou Biosciences (CRBU), Cardiol Therapeutics (CRDL), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. Lantern Pharma vs. Its Competitors Galectin Therapeutics Greenwich LifeSciences Rapt Therapeutics Neumora Therapeutics FitLife Brands Actuate Therapeutics Fate Therapeutics Caribou Biosciences Cardiol Therapeutics Korro Bio Lantern Pharma (NASDAQ:LTRN) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Do insiders & institutionals have more ownership in LTRN or GALT? 28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 7.3% of Lantern Pharma shares are owned by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate LTRN or GALT? Lantern Pharma currently has a consensus price target of $25.00, indicating a potential upside of 525.00%. Galectin Therapeutics has a consensus price target of $6.00, indicating a potential upside of 109.79%. Given Lantern Pharma's higher probable upside, equities research analysts clearly believe Lantern Pharma is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, LTRN or GALT? Lantern Pharma has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Which has stronger earnings and valuation, LTRN or GALT? Galectin Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantern PharmaN/AN/A-$20.78M-$1.84-2.17Galectin TherapeuticsN/AN/A-$47.05M-$0.72-3.97 Is LTRN or GALT more profitable? Galectin Therapeutics' return on equity of 0.00% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lantern PharmaN/A -83.26% -70.65% Galectin Therapeutics N/A N/A -216.05% Does the media prefer LTRN or GALT? In the previous week, Lantern Pharma and Lantern Pharma both had 3 articles in the media. Galectin Therapeutics' average media sentiment score of 0.85 beat Lantern Pharma's score of 0.19 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLantern Pharma beats Galectin Therapeutics on 6 of the 10 factors compared between the two stocks. Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LTRN vs. The Competition Export to ExcelMetricLantern PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.10M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-2.1720.3528.6119.64Price / SalesN/A304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book2.047.718.185.63Net Income-$20.78M-$55.11M$3.23B$257.73M7 Day Performance17.99%0.68%-0.25%0.07%1 Month Performance25.00%8.22%5.40%8.32%1 Year Performance-11.11%-2.64%26.35%13.78% Lantern Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LTRNLantern Pharma2.9864 of 5 stars$4.00+6.4%$25.00+525.0%-13.6%$43.10MN/A-2.1720News CoveragePositive NewsGALTGalectin Therapeutics2.2471 of 5 stars$2.15-1.4%$6.00+179.1%+17.6%$137.98MN/A-2.999Gap UpGLSIGreenwich LifeSciences2.1494 of 5 stars$10.07+0.4%$39.00+287.3%-35.6%$134.08MN/A-7.993RAPTRapt Therapeutics4.3508 of 5 stars$8.16+1.4%$24.00+194.1%-62.9%$133.12M$1.53M-0.4280Trending NewsAnalyst RevisionNMRANeumora Therapeutics2.7245 of 5 stars$0.90+9.0%$7.50+737.7%-87.5%$132.89MN/A-0.56108News CoveragePositive NewsAnalyst ForecastGap UpFTLFFitLife Brands4.0475 of 5 stars$13.75-2.8%$20.50+49.1%-19.3%$132.79M$64.47M16.3720ACTUActuate Therapeutics2.7248 of 5 stars$6.01-8.8%$20.50+241.1%N/A$129.29MN/A0.0010Positive NewsFATEFate Therapeutics3.6202 of 5 stars$1.06-5.4%$3.83+261.6%-71.0%$128.36M$13.63M-0.71550Gap UpCRBUCaribou Biosciences2.9088 of 5 stars$1.39+1.5%$8.50+511.5%-24.4%$127.42M$9.99M-0.86100Positive NewsCRDLCardiol Therapeutics2.4309 of 5 stars$1.45-5.8%$8.00+451.7%-39.4%$127.28MN/A-4.2620Positive NewsKRROKorro Bio1.5125 of 5 stars$12.58-5.8%$102.43+714.2%-74.3%$125.36M$2.27M-1.3370 Related Companies and Tools Related Companies GALT Alternatives GLSI Alternatives RAPT Alternatives NMRA Alternatives FTLF Alternatives ACTU Alternatives FATE Alternatives CRBU Alternatives CRDL Alternatives KRRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LTRN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LTRN Stock Alerts